Reglagene is a therapeutics company that leverages its expertise in the design and development of brain penetrant medicines to create breakthrough therapies for primary brain cancers and brain metastases from extracranial cancers. RGN6024 offers a blend of oral administration, safety, and unparalleled penetration of the blood-brain barrier. Currently in preclinical development, RGN6024 shows promise for treating brain cancers, notably outperforming temozolomide—the current SOC— in glioblastoma and increases survival in a rigorous intracranial model. Supported by a concise 3-step manufacturing process, robust pharmacokinetic profiles and favorable toxicity data, Reglagene is advancing RGN6024 towards clinical trials, with an IND filing projected for early 2025. We are currently raising a Convertible Note to take our lead program through IND filing. By strategically capitalizing on our patented technology, our second product will address neuroinflammation.